Incyte reported fourth-quarter net income of $299.3 million, or $1.46 per share, a sharp increase from the $201.2 million recorded during the same period last year. However, adjusted earnings of $1.80 per share missed the $1.90 consensus estimate tracked by FactSet. Total revenue climbed 28% to $1.51 billion, comfortably exceeding analyst targets of $1.36 billion, driven largely by steady demand for its core oncology and dermatology portfolios.

Sales of the blood cancer drug Jakafi rose 7% to $828.2 million, while Opzelura, a prescription skin cream, saw a 28% surge to $207.3 million. Despite these gains, investors focused on the road ahead. Incyte shares fell as much as 10% in early trading before settling at $101.07, down 7.3% by the afternoon session.

The 2026 Revenue Outlook

The company’s long-term guidance suggests a potential slowdown for key products compared to market expectations. For 2026, Incyte expects total net product revenue to fall between $4.77 billion and $4.94 billion. While the total range encompasses the $4.89 billion market estimate, specific product forecasts disappointed investors:

• Jakafi revenue is projected between $3.22 billion and $3.27 billion.
• Opzelura revenue is expected to reach $750 million to $790 million, trailing the $816 million modeled by analysts.
• Total net product revenue is centered around a $4.89 billion estimate.

Looking ahead, the company plans to expand its commercial footprint through new regulatory milestones. Incyte expects to submit a commercialization application for povorcitinib, a treatment for chronic skin conditions, to the U.S. Food and Drug Administration during the first quarter. This move is part of a broader effort to diversify revenue as the company navigates the competitive oncology landscape.